Potential of Ivonescimab in MSS Colorectal Cancer
Unmet Need in MSS Colorectal Cancer
Colorectal cancer (CRC) ranks as the third most common cancer globally and the second leading cause of cancer deaths, with approximately 1.9 million new cases and 900,000 deaths in 2022 (Morgan et al., Gut 2023; IARC). About 85–95% of CRC cases are microsatellite stable (MSS) or mismatch repair proficient (pMMR). No immunotherapy is currently approved for first-line treatment of MSS CRC.
Standard first-line treatments for metastatic MSS CRC typically involve chemotherapy (e.g., FOLFOX or FOLFIRI) combined with targeted therapies like bevacizumab (anti-VEGF) or, for RAS wild-type cases, EGFR inhibitors (cetuximab or panitumumab). These regimens yield:
Doublet chemotherapy + bevacizumab: Objective response rate (ORR) of ~50% and median progression-free survival (PFS) of 9–10 months (Targeted Oncology, Bendell 2016).
Triplet chemotherapy (FOLFOXIRI) + bevacizumab: Improved ORR of 60–65% and median PFS of 11–12 months, but with higher toxicity (STEAM, TRIBE trials).
Despite these options, five-year survival remains below 20%, and chemo resistance limits durable remission. For specific cases like BRAF V600E-mutant CRC, targeted inhibitors can improve outcomes, but most MSS CRC patients lack such actionable biomarkers.
Previous immunotherapy trials, such as CheckMate-9X8 (nivolumab + chemo/bevacizumab) and NCT03050814 (chemo + vaccine + avelumab), showed ORRs of 50–60% but no significant PFS improvement over standard therapy (Lenz et al., 2022; Redman et al., 2022).
Promising Results of Ivonescimab in Phase II Trials
Ivonescimab (AK112) has shown unprecedented results in its Phase II trial for first-line MSS CRC. Key findings include:
Ivonescimab + chemotherapy: Achieved an ORR of 81.8% (18/22 patients with partial responses, no progression) and a disease control rate (DCR) of 100% (Akeso, ESMO 2024).
Ivonescimab + ligufalimab + chemotherapy: ORR reached 88.2%, suggesting enhanced efficacy by targeting CD47, a “don’t-eat-me” signal (Akeso, ESMO 2024).
Progression-Free Survival: After ~9 months of follow-up, median PFS was not reached, with a 9-month PFS rate of 81.4% for Ivonescimab + chemotherapy, far surpassing the ~50% seen with standard regimens at 9 months (CheckMate-9X8, TRIBE). Investigators project a potential median PFS of 15–20 months with further follow-up.
These results significantly outperform historical benchmarks (ORR ~50–60%, PFS ~10–12 months).
Conclusion
If the Phase III trial (AK112-312/HARMONi-GI6) succeeds and Ivonescimab gains approval for first-line MSS mCRC treatment, its market value could reach USD 15–25 billion by 2030. This estimate assumes 20% market penetration, pricing at USD 15,000–20,000/month, and a 4x revenue multiple.
References
Morgan et al., Gut 2023: Global CRC burden (~1.9M cases, 900k deaths).
IARC 2022: CRC is 85–95% MSS/pMMR, unresponsive to immunotherapy.
Akeso, ESMO 2024: Ivonescimab + chemo in MSS CRC: ORR 81.8%, DCR 100%, 9-mo PFS 81.4%.
Lenz et al., 2022 GI Symposium: CheckMate-9X8, ORR 60% vs 46%, mPFS 11.9 mo (no improvement).
Redman et al., Oncologist 2022: NCT03050814, ORR ~50%, mPFS ~10.1 mo.
Bendell, Targeted Oncology 2016: FOLFOXIRI+bev vs FOLFOX+bev, ORR 60% vs 47%, PFS 11.4 vs 9.3 mo.